Literature DB >> 3687320

Cytostatics for acromegaly. Marked improvement in a patient with an invasive pituitary tumour.

A A Kasperlik-Zaluska1, J Wislawski, J Kaniewska, J Zborzil, E Frankiewicz, S Zgliczyński.   

Abstract

A 21-year-old woman suffering from acromegaly was treated with transsphenoidal subtotal hypophysectomy (microscopy: acidophilic adenoma), followed by x-ray and bromocriptine therapy. Seven years later she was re-operated because of a partial bitemporal loss of vision, intracranial hypertension, and regrowth of the pituitary tumour seen on CT-scan. A large part of the invasive suprasellar tumour was then removed by transcranial approach. The neurosurgery was followed by cobalt radiotherapy and bromocriptine administration. Two years later, symptoms and signs of tumour growth reappeared. Administration of cytostatics, such as doxorubicin (Adriamycin) and lomustine (Belustine), resulted in distinct clinical improvement associated with a seven-fold decrease in the serum growth hormone concentration. The visual field became normal and the intracranial mass on a CT scan decreased markedly. As a result the patient was able to resume work.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3687320

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  4 in total

Review 1.  Malignant pituitary tumours.

Authors:  G A Kaltsas; A B Grossman
Journal:  Pituitary       Date:  1998-04       Impact factor: 4.107

2.  Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression.

Authors:  Zachary M Bush; Janina A Longtine; Tracy Cunningham; David Schiff; John A Jane; Mary Lee Vance; Michael O Thorner; Edward R Laws; M Beatriz S Lopes
Journal:  J Clin Endocrinol Metab       Date:  2010-07-28       Impact factor: 5.958

Review 3.  Management of aggressive pituitary adenomas and pituitary carcinomas.

Authors:  Anthony Heaney
Journal:  J Neurooncol       Date:  2014-03-02       Impact factor: 4.130

4.  Doxorubicin for acromegaly: a case report.

Authors:  R Attanasio; P Orlandi; D Dallabonzana; A Lodrini; M Ferrari; E Maccagnano; G Verde; R Cozzi; A Liuzzi; P G Chiodini
Journal:  J Endocrinol Invest       Date:  1991-06       Impact factor: 4.256

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.